Want to see BCAX full AI Analyst Report?
BCAX Stock Chart & Stats
$27.02
$0.79(2.92%)
At close: 4:00 PM EDT
$27.02
$0.79(2.92%)
Day’s Range― - ―
52-Week Range$10.30 - $30.99
Previous Close$27.81
Volume499.45K
Average Volume (3M)829.98K
Market Cap
$1.61B
Enterprise Value$1.52K
Total Cash (Recent Filing)$497.26M
Total Debt (Recent Filing)$1.16M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Nov 17, 2026EPS Estimate
-0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.10
Shares Outstanding66,172,935
10 Day Avg. Volume408,617
30 Day Avg. Volume829,976
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)2.29
Price to Sales (P/S)0.00
P/FCF Ratio-8.59
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$33.18Price Target Upside22.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.47
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Durable 3-year Efficacy SignalThree-year survival data showing roughly one in three patients alive at three years at the pivotal dose represent a durable clinical benefit signal. That level of differentiated efficacy materially de-risks Phase III readouts, strengthens future label/market positioning, and supports long-term uptake by clinicians and payers if confirmed.
Multi‑year Cash RunwayNearly $500M in liquidity funds pivotal OS readout, potential regulatory filing, manufacturing scale-up and initial commercial investments. A multi-year runway reduces immediate financing pressure, permitting focused execution on clinical milestones and commercialization planning without forcing near-term dilution.
Low Leverage And Sizable Equity BaseVery low debt and a large equity base provide financial flexibility to sustain R&D and absorb near-term operational ramps. This balance sheet strength supports continued trial execution, potential partnership negotiations, and commercial buildout choices without being constrained by heavy interest or refinancing obligations.
Bears Say
Pre‑revenue With Widening LossesThe company remains pre-revenue with materially widening net losses over recent years. Persistent negative earnings means long-term value creation depends entirely on clinical and regulatory success; failure or delays could force dilutive financings and impair shareholder returns over the medium term.
Weak Cash Generation, High BurnOperating cash flow and free cash flow are consistently negative and worsening, indicating current operations consume cash rather than generate it. Even with existing runway, continued burn—especially as commercial and manufacturing investments increase—creates risk of further funding needs if milestones slip.
Competitive And Regulatory Timing RiskMultiple rival programs and near-term readouts could alter treatment sequencing, pricing, or market share. Additionally, dosing-regimen labeling for the alternative FORTIFI-FLEX approach is not assured. Both competitive dynamics and regulatory uncertainty can compress commercial opportunity and complicate adoption even if approval is achieved.
Bicara Therapeutics Inc. News
BCAX FAQ
What was Bicara Therapeutics Inc.’s price range in the past 12 months?
Bicara Therapeutics Inc. lowest stock price was $10.29 and its highest was $30.99 in the past 12 months.
What is Bicara Therapeutics Inc.’s market cap?
Bicara Therapeutics Inc.’s market cap is $1.61B.
When is Bicara Therapeutics Inc.’s upcoming earnings report date?
Bicara Therapeutics Inc.’s upcoming earnings report date is Nov 17, 2026 which is in 92 days.
How were Bicara Therapeutics Inc.’s earnings last quarter?
Bicara Therapeutics Inc. released its earnings results on Aug 11, 2026. The company reported -$0.82 earnings per share for the quarter, the consensus estimate of -$0.82 by $0.
Is Bicara Therapeutics Inc. overvalued?
According to Wall Street analysts Bicara Therapeutics Inc.’s price is currently Undervalued.
Does Bicara Therapeutics Inc. pay dividends?
Bicara Therapeutics Inc. does not currently pay dividends.
What is Bicara Therapeutics Inc.’s EPS estimate?
Bicara Therapeutics Inc.’s EPS estimate is -0.85.
How many shares outstanding does Bicara Therapeutics Inc. have?
Bicara Therapeutics Inc. has 66,172,935 shares outstanding.
What happened to Bicara Therapeutics Inc.’s price movement after its last earnings report?
Bicara Therapeutics Inc. reported an EPS of -$0.82 in its last earnings report, expectations of -$0.82. Following the earnings report the stock price went down -14.317%.
Which hedge fund is a major shareholder of Bicara Therapeutics Inc.?
Currently, no hedge funds are holding shares in BCAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bicara Therapeutics Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$33.18 (22.80% Upside)
$33.18 (22.80% Upside)
Blogger Sentiment
Bullish
BCAX Sentiment 100%
Sector Average 59%
Sector Average 59%
Hedge Fund Trend
Increased
By 474.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 28.6%
Last 30 Days ▲ 28.6%
News Sentiment
Very Bullish
Bullish news 90%
Bearish news 10%
Bearish news 10%
Technicals
SMA
Positive
20 days / 200 days
Momentum
126.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.93%
Trailing 12-Months
Company Description
Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
BCAX Company Deck
BCAX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and operational momentum: mature 3-year efficacy and safety data for Ficera (≈33% 3-year survival, ~2x SOC), clear milestones (interim OS analysis mid-2027), initiation of an alternative dosing study timed for potential approval, and a planned leadership succession to support commercialization. These positives are balanced against rising operating expenses and planned commercialization spend, competitive timing uncertainty from other EGFR-directed agents, and small early CRC cohorts that will require further validation. Overall, the highlights—particularly the robust long-term efficacy signal, funded runway into H1 2029, and deliberate commercialization preparations—outweigh the near-term execution and competitive risks.View all BCAX earnings summariesBCAX Stock 12 Month Forecast
Average Price Target
$33.18
▲(22.80% Upside)
Technical Analysis
Sarepta Therapeutics
―
Wave Life Sciences
―
Intellia Therapeutics
―
Stoke Therapeutics
―
Taysha Gene Therapies
―
Ownership Overview
21.71% Insiders
16.05% Mutual Funds
19.34% Other Institutional Investors
32.18% Public Companies and
Individual Investors